Status:
COMPLETED
The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes
Lead Sponsor:
Rockefeller University
Conditions:
Paraneoplastic Syndromes
Eligibility:
All Genders
1+ years
Brief Summary
The investigators believe that T cells, cells that are a part of the immune system, are what are causing the neurological problems while also attacking tumor cells. This protocol studies the clinical ...
Detailed Description
Patients with paraneoplastic neurological disorders (PNDs) provide a unique model for studying tumor immunity and neuronal autoimmunity. We hypothesize that T lymphocyte autoimmune dysfunction is invo...
Eligibility Criteria
Inclusion
- Neurological disease which is suspected to be paraneoplastic
- No known active additional malignancy other than non-melanoma skin cancer
Exclusion
- Known central nervous system (CNS) metastasis
- Known active additional malignancy
- No pulmonary disease which limits daily activities
- if leukapheresis: must be 14 or older no known hepatitis B or C, HIV, or syphilis (by history or prior negative tests) no known IV drug users HgB \> 8.5 WBC \> 3,500 platelets \> 100,000 INR \< 2
- if large blood draw (1/2 to 1 unit; children 3 ml/kg) in lieu of leukapheresis: no known IV drug users HgB \> 10 WBC \> 3,500 platelets \> 100,000 INR \< 2
- if lumbar puncture: platelets \> 120,000 INR \< 1.2 must be 14 or older
Key Trial Info
Start Date :
January 1 1995
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2018
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT00327236
Start Date
January 1 1995
End Date
February 1 2018
Last Update
April 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rockefeller University Hospital
New York, New York, United States, 10021